Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 10:15:1542453.
doi: 10.3389/fphar.2024.1542453. eCollection 2024.

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

Irma Convertino  1 , Luciane Cruz Lopes  2 , Nicole Pratt  3 , Ylenia Ingrasciotta  4 , Marco Tuccori  4
Affiliations
Editorial

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

Irma Convertino et al. Front Pharmacol. .
No abstract available

Keywords: DMARDs; biologic drugs; cost-effectiveness; immune-mediated inflammatory diseases; pharmacoepidemiology; real-world data; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Comment on

  • Editorial on the Research Topic Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

References

    1. Blandizzi C., Meroni P. L., Lapadula G. (2017). Comparing originator biologics and biosimilars: a review of the relevant issues. Clin. Ther. 39 (5), 1026–1039. 10.1016/j.clinthera.2017.03.014 - DOI - PubMed
    1. Convertino I., Lorenzoni V., Gini R., Turchetti G., Fini E., Giometto S., et al. (2023). Drug-utilization, healthcare facilities accesses and costs of the first generation of JAK inhibitors in rheumatoid arthritis. Pharmaceuticals 16 (3), 465. 10.3390/ph16030465 - DOI - PMC - PubMed
    1. Convertino I., Lucenteforte E., Gini R., Lorenzoni V., Cazzato M., Turchetti G., et al. (2021). Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons. Clin. Exp. Rheumatol. 39 (4), 753–762. 10.55563/clinexprheumatol/pa6lap - DOI - PubMed
    1. El-Gabalawy H., Guenther L. C., Bernstein C. N. (2010). Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J. Rheumatol. Suppl. 85, 2–10. 10.3899/jrheum.091461 - DOI - PubMed
    1. Ferraro S., Cappello E., Bartolini C., Convertino I., Bertani L., Lucenteforte E., et al. (2023). Potential missed diagnoses of Crohn’s disease in tertiary care: impact on drug utilization and healthcare facilities use. Eur J Gastroenterol Hepatol. 5 (11), 1263–1269. 10.1097/MEG.0000000000002642 - DOI - PubMed

Publication types

LinkOut - more resources